Premier (NASDAQ:PINC) Stock, Quote.Headers.trade-ideas

Premier

Premier Inc is a Charlotte, North Carolina-based technology-driven healthcare improvement company, uniting an alliance of United States (U.S.) hospitals, health systems, and other providers and organizations to transform healthcare. The company's revenue is all sourced domestically and is reported in two business segments: the supply chain services and the consulting and technology platform of performance services. It generates the majority of its revenue from the supply chain services segment.

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

PINC

Wall Street&#39;s Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Ardelyx ARDX

Large Cap

Health Care

Legal

General

FTC probes chemotherapy shortages, scrutinizing drug distributors and hospital groups. Root causes of drug shortages under scrutiny. Industry defends practices.

US Federal Trade Commission Investigates Drug Shortages Amid Allegations Of Market Manipulation

premier Health-Wikimedia Commons

Earnings

Guidance

Buybacks

Movers

Premier charts a strategic path with a $1.0 billion share repurchase plan through June 2025. Q2 2024 earnings: EPS $0.60, sales $334.75 million

Healthcare Purchasing Network Premier Launches $1B Share Buyback Program, Concludes Strategic Review Process After Q2 Performance

Premier Inc

Canaccord Genuity analyst Richard Close maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Hold and raises the price target from $19 to $21.

Canaccord Genuity Maintains Hold on Premier, Raises Price Target to $21

Barclays analyst Stephanie Davis maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Equal-Weight and raises the price target from $20 to $24.

Barclays Maintains Equal-Weight on Premier, Raises Price Target to $24

5 analysts have shared their evaluations of Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Premier and provided 12-month price targets. The average target is $19.4, accompanied by a high estimate of $20.00 and a low estimate of $19.00. Highlighting a 5.83% decrease, the current average has fallen from the previous average price target of $20.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1730898081_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Premier among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Premier. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Premier compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Premier's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PINC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Premier analyst ratings.</a>
<h2>Delving into Premier's Background</h2>
Premier Inc is a Charlotte, North Carolina-based technology-driven healthcare improvement company, uniting an alliance of United States (U.S.) hospitals, health systems, and other providers and organizations to transform healthcare. The company's revenue is all sourced domestically and is reported in two business segments: the supply chain services and the consulting and technology platform of performance services. It generates the majority of its revenue from the supply chain services segment.
<h3>Key Indicators: Premier's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Premier's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.91% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 17.32%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Premier's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.12%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Premier's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.79%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.06, Premier adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 5 Analyst Insights On Premier

Baird analyst Eric Coldwell maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Neutral and raises the price target from $19 to $20.

Baird Maintains Neutral on Premier, Raises Price Target to $20

WIIM

Premier shares are trading higher after the company reported better-than-expected Q1 financial results.

Fiscal 2025 Guidance
Certain statements in this release, including without limitation, those in this section, are forward-looking statements. For additional information regarding the use and limitations of such statements, refer to "Cautionary Note Regarding Forward-Looking Statements" below.
Based on results for the first quarter of fiscal 2025 and its current outlook for the remainder of the fiscal year, the company is reaffirming the following:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Guidance Metric</td>
<td colspan="1" rowspan="1">Fiscal 2025 Guidance Range [1] [2] (as of November 5, 2024)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Segment Net Revenue:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Supply Chain Services</td>
<td colspan="1" rowspan="1">$560 million to $610 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Performance Services Excluding Contigo Health</td>
<td colspan="1" rowspan="1">$370 million to $410 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Net Revenue Excluding Contigo Health</td>
<td colspan="1" rowspan="1">$930 million to $1.02 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$235 million to $255 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">$1.16 to $1.28</td>
</tr>
<tr>
<td colspan="2" rowspan="1">
Fiscal 2025 guidance is based on the realization of the following key assumptions:
<ul>
<li>Net administrative fees revenue of $495 million to $525 million, which includes $60 million to $75 million in revenue related to non-healthcare member purchasing</li>
<li>Supply Chain Services segment software licenses, other services and support revenue of $65 million to $85 million</li>
<li>Capital expenditures of $90 million to $100 million</li>
<li>Effective income tax rate in the range of 25% to 27%</li>
<li>Cash income tax rate of less than 5%</li>
<li>Free cash flow of 45% to 55% of adjusted EBITDA</li>
</ul>
</td>
</tr>
</tbody>
</table>
</figure>

Premier Expects FY25 Net Revenue Of $930M-$1.02B Vs $977.19M Est, Adj EPS Of $1.16-$1.28 Vs $1.21 Est

Earnings Beats

Premier Q1 2025 Adj. EPS $0.34 Beats $0.25 Estimate, Sales $248.142M Beat $232.843M Estimate

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Organon &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>)</h3>
<ul>
<li>Dividend Yield: 6.36%</li>
<li>JP Morgan analyst Chris Schott downgraded the stock from Neutral to Underweight and raised the price target from $18 to $20 on Sept. 6. This analyst has an accuracy rate of 60%.</li>
<li>Piper Sandler analyst David Amsellem maintained an Overweight rating and raised the price target from $22 to $24 on April 29. This analyst has an accuracy rate of 68%</li>
<li>Recent News: Organon will release its third quarter financial results on Oct. 31.</li>
<li>Benzinga Pro's real-time newsfeed alerted to l<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1">atest OGN news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21054143/image-181.png" alt="" class="wp-image-604777" style="width:681px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21054143/image-181.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21054143/image-181-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21054143/image-181-768x717.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<h3 class="wp-block-heading">Premier, Inc. &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>)</h3>
<ul>
<li>Dividend Yield: 4.15%</li>
<li>Benchmark analyst Bill Sutherland downgraded the stock from Buy to Hold on Aug. 26. This analyst has an accuracy rate of 64%.</li>
<li>Baird analyst Eric Coldwell maintained a Neutral rating and cut the price target from $22 to $19 on Aug. 21. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: Premier will release financial results for its fiscal 2025 first quarter on Tuesday, Nov. 5.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1"> latest PINC news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21050948/image-178.png" alt="" class="wp-image-604724" style="width:700px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21050948/image-178.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21050948/image-178-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21050948/image-178-768x706.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)</h3>
<ul>
<li>Dividend Yield: 3.97%</li>
<li>Jefferies analyst Peter Welford maintained a Buy rating and raised the price target from $52.5 to $53 on July 2. This analyst has an accuracy rate of 68%.</li>
<li>Guggenheim analyst Seamus Fernandez upgraded the stock from Neutral to Buy on March 4. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Oct. 16, the FDA accepted GSK's marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with uncomplicated urinary tract infections (uUTIs).</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1">trend in GSK stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="920" height="852" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21051023/image-179.png" alt="" class="wp-image-604726" style="width:654px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21051023/image-179.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21051023/image-179-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21051023/image-179-768x711.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41421321/dow-s-p-500-settle-at-record-high-levels-record-6th-consecutive-week-of-gains-fear-index-moves-to-e">Dow, S&amp;P 500 Settle At Record High Levels, Record 6th Consecutive Week Of Gains: Fear Index Moves To &#8216;Extreme Greed&#8217; Zone</a></li>
</ul>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $19.25, a high estimate of $20.00, and a low estimate of $19.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.33%. 
<img src="https://www.benzinga.com/files/images/story/2024/1727884883_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Premier by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Premier. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Premier compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Premier's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Premier's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PINC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Premier analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Premier</h2>
Premier Inc is a Charlotte, North Carolina-based technology-driven healthcare improvement company, uniting an alliance of United States (U.S.) hospitals, health systems, and other providers and organizations to transform healthcare. The company's revenue is all sourced domestically and is reported in two business segments: the supply chain services and the consulting and technology platform of performance services. It generates the majority of its revenue from the supply chain services segment.
<h3>Breaking Down Premier's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Premier displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 2.91%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Premier's net margin is impressive, surpassing industry averages. With a net margin of 17.32%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Premier's ROE stands out, surpassing industry averages. With an impressive ROE of 3.12%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Premier's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.79% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Premier's debt-to-equity ratio is below the industry average. With a ratio of 0.06, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Premier: Insights From 4 Financial Analysts

Canaccord Genuity analyst Richard Close maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Hold and lowers the price target from $20 to $19.

Canaccord Genuity Maintains Hold on Premier, Lowers Price Target to $19

<a href="https://premierinc.com/newsroom/press-releases/premier-inc-and-long-grove-pharmaceuticals-join-forces-to-increase-supply-of-norepinephrine-iv-bags" title="https://premierinc.com/newsroom/press-releases/premier-inc-and-long-grove-pharmaceuticals-join-forces-to-increase-supply-of-norepinephrine-iv-bags">https://premierinc.com/newsroom/press-releases/premier-inc-and-long-grove-pharmaceuticals-join-forces-to-increase-supply-of-norepinephrine-iv-bags</a>

Premier And Long Grove Pharmaceuticals Partner To Increase Supply Of Norepinephrine IV Bags, Addressing Ongoing Shortages And Ensuring Long-Term Availability For Critical Care

Pursuant to the partnership agreement, Premier exchanged all its holdings in the S2S Global business, its direct sourcing subsidiary, for a&nbsp;20 percent&nbsp;minority interest in Prestige.
This new ownership interest is in addition to an existing indirect investment that Premier made in the company in 2020, increasing Premier&#39;s total ownership (direct and indirect) interest in Prestige to approximately&nbsp;24.2 percent&nbsp;in the aggregate.
&nbsp;

Asset Sales

Premier, Inc. Enters Partnership With Prestige Ameritech; Divests Ownership Position In S2S Global

JP Morgan analyst Anne Samuel maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Neutral and lowers the price target from $21 to $19.

JP Morgan Maintains Neutral on Premier, Lowers Price Target to $19

Benchmark analyst Bill Sutherland downgrades Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) from Buy to Hold.

Downgrades

Benchmark Downgrades Premier to Hold

Canaccord Genuity analyst Richard Close maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Hold and lowers the price target from $21 to $20.

Canaccord Genuity Maintains Hold on Premier, Lowers Price Target to $20

Baird analyst Eric Coldwell maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Neutral and lowers the price target from $22 to $19.

Baird Maintains Neutral on Premier, Lowers Price Target to $19

Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.49 by 40.82 percent. This is a 2.99 percent increase over earnings of $0.67 per share from the same period last year. The company reported quarterly sales of $350.27 million which beat the analyst consensus estimate of $313.21 million by 11.83 percent. This is a 2.91 percent increase over sales of $340.36 million the same period last year.

Premier Q4 Adj $0.69 Beats $0.49 Estimate, Sales $350.27M Beat $313.21M Estimate

Coleman will succeed Craig McKasson, who will retire on December 31, 2024, and will serve as a strategic advisor to the company through 2026.

Management

Premier, Inc. Names Glenn Coleman As The Chief Administrative And Financial Officer, Effective November 11, 2024

<ul>
<li>Partnership to support more than $3.5 billion in AllSpire annual GPO purchasing volume.</li>
<li>Premier supply chain services and performance improvement technology to enable operational efficiency, supply chain innovation and value​ for AllSpire members.</li>
</ul>

Contracts

AllSpire Health Partners Selects Premier As National GPO

Teleflex Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>), a leading global provider of medical technologies, today announced it was awarded two group purchasing agreements with Premier, Inc. Effective July 1, 2024, the Premier National Hemostasis Products and SURPASS&reg; Hemostasis Products agreements allow Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex products within the hemostatic portfolio. 
&nbsp;
Premier&#39;s SURPASS&reg; program is designed to drive the highest-level commitment and savings for members through aggregated purchasing of high-quality products and services. The program brings together Premier&#39;s most committed members to coordinate purchasing decisions and maintain standardization across their facilities. By providing additional value to Premier contracted suppliers through volume and commitment, the program is expected to achieve best-in-market pricing.
QuikClot&trade; Hemostatic Dressings and Devices control bleeding faster than standard gauze or laparotomy pads,1-3&nbsp;enabling clinicians to move patients to the next stage of care quickly. The portfolio includes a range of products to support clinicians throughout the hospital, including in the Emergency Department, Operating Room, Intensive Care Unit, and Catheterization Lab.

Teleflex Secures Premier Agreements for Hemostasis Products with Special Pricing

Barclays raised the firm's price target on Premier (PINC) to $24 from $20 and keeps an Equal Weight rating on the shares following the fiscal Q1 re...

Premier price target raised to $24 from $20 at Barclays

Baird analyst Eric Coldwell raised the firm's price target on Premier (PINC) to $20 from $19 and keeps a Neutral rating on the shares. The firm sai...

Premier price target raised to $20 from $19 at Baird

Piper Sandler analyst Jessica Tassan maintained a Hold rating on Premier (PINC – Research Report) today and set a price target of $21.00. The compa...

Premier (PINC) Gets a Hold from Piper Sandler

TeleVox has been awarded a national group purchasing agreement for AI chatbots with Premier (PINC), the agreement allows Premier members, at their ...

TeleVox awarded AI chatbot agreement with PremierPremier

Premier (PINC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 5. Analyst Michael Cherny from ...

Premier's Market Position Stable Amid Mixed Segment Performance and Growth Concerns

In a report released today, Bill Sutherland from Benchmark Co. reiterated a Hold rating on Premier (PINC – Research Report). The company's shares c...

Benchmark Co. Keeps Their Hold Rating on Premier (PINC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Premier (PINC – Research Report) and Roche Holding AG (RHHVF – Re...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Premier (PINC) and Roche Holding AG (OtherRHHVF)

Elutia (ELUT) announced it has been awarded a national group purchasing agreement for Cardiac Rhythm Management Devices with Premier (PINC). Effect...

Elutia awarded cardian rhythm management devices agreement with Premier

Premier ( ($PINC) ) has shared an announcement. Premier, Inc. has appointed David Zito as President of its Performance Services, effective December...

Premier, Inc. Announces New Leadership Appointment

OUSM: Low-Volatility Small Cap ETF Beating The Benchmark

DGRS

ELUT

LECO

OUSM

RHHVF

SEIC

SMDV

TXRH

Press Releases

Premier, Inc. to Report Fiscal 2024 Fourth-Quarter and Full-Year Results and Host Conference Call on August 20, 2024

Premier, Inc. Declares Quarterly Cash Dividend

AllSpire Health Partners Selects Premier, Inc. as its National GPO

Premier, Inc. Reports Fiscal-Year 2024 Fourth-Quarter and Full-Year Results

Premier, Inc. Appoints Glenn Coleman as Chief Administrative and Financial Officer

Premier, Inc. Divests Ownership Position in S2S Global Through New Partnership With Prestige Ameritech

Premier, Inc. to Report Fiscal 2025 First-Quarter Results and Host Conference Call on November 5, 2024

Premier, Inc. Reports Fiscal-Year 2025 First-Quarter Results

Premier, Inc. Appoints David Zito as President, Performance Services

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Premier

Premier (PINC) Forecast

Premier (NASDAQ:PINC) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga